DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Rosacea phenotypes and treatment

Essential points for quick revision.

Synopsis

Recognise overlapping vascular, inflammatory, ocular and phymatous rosacea features across skin tones, exclude important mimics, and select phenotype-directed skin care, topical, systemic and referral options.

  • Diagnose by features rather than rigid subtypes: persistent centrofacial erythema, flushing, telangiectasia, papules or pustules, ocular disease and phymatous change overlap.
  • Comedones are not a rosacea feature; their presence suggests acne coexistence or an alternative diagnosis.
  • In darker skin, persistent erythema may appear dusky, violaceous or brown and is often detected more reliably through warmth, burning, swelling, photographs and dermoscopy.

Key red flags

Eye pain, photophobia, reduced vision, marked corneal redness, rapidly progressive facial swelling, systemic illness or an atypical scarring or photosensitive eruption needs urgent ophthalmic or diagnostic assessment rather than routine rosacea treatment.

Sight-threatening ocular disease

Eye pain, photophobia, reduced acuity or corneal opacity suggests keratitis or ulceration and requires urgent same-day ophthalmic assessment.

Investigation priorities

01
Feature-led skin and eye examinationFirst step

Document dominant phenotype, severity and urgent ocular findings.

Management branches

Papulopustular phenotypeSuppress inflammatory lesions

Facial papules or pustules occur without comedones and without sight-threatening ocular features.

  1. Start gentle cleanser, non-comedogenic moisturiser and SPF 30 or higher, remove inappropriate facial corticosteroid exposure through a planned approach, and agree one topical anti-inflammatory option.
  2. Use ivermectin once daily, azelaic acid twice daily or metronidazole twice daily according to the chosen product; apply away from eyes and set the product-specific response point.
Ocular or phymatous diseaseEscalate beyond routine facial care

Persistent lid or eye symptoms, corneal warning features or established tissue thickening is present.

Key medicines

Ivermectin 10 mg/g creamApply one pea-sized amount to each of five facial areas once daily for up to four months, spreading a thin layer and avoiding eyes, lips and mucosa.
Azelaic acid 15% gelApply about 0.5 g, a 2.5 cm strip, to the whole face twice daily after cleansing; reduce frequency or interrupt briefly if irritation is troublesome.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom